MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- INDOCO REMEDIES
INDOCO REMEDIES Share Price (INDOCO)
Here is the latest stock price and chart of Indoco Remedies. For more details, see the Indoco Remedies company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Mar 27, 2020 (Close) | ||
|---|---|---|---|
| Price (Rs)183.95 | Open (Rs) 195.95 | High (Rs) 195.95 | Low (Rs) 181.05 |
| % Change1.80 | Volume 2,191 | Value (Rs) 403,046 | 52-Week H/L 272.40 / 133.10 |
| Live NSE Quotes | Mar 27, 2020 (Close) | ||
|---|---|---|---|
| Price (Rs)184.45 | Open (Rs) 180.20 | High (Rs) 196.70 | Low (Rs) 180.00 |
| % Change1.79 | Volume 24,478 | Value (Rs) 4,560,632 | 52-Week H/L 272.50 / 132.45 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 3.31 | P/E Ratio (x) 55.63 | Market Cap (Rs m) 16,955.59 | P/BV (x) 2.51 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
INDOCO REMEDIES Share Price Today:
INDOCO REMEDIES last traded price was up 1.8% to Rs 184.0 on the BSE. On the NSE, INDOCO REMEDIES last traded price was up 1.8% to Rs 184.5. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.2%. And the benchmark S&P BSE SENSEX was at 29,815.6 (down 0.4%).
Over the last 30 days, the INDOCO REMEDIES share price is down 30.3%. And over the last one year, INDOCO REMEDIES share price is down 0.0%.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- BSE A Group Gainers Today
- NSE Above Rs 20 Gainers Today
- BSE Above Rs 20 Gainers Today
- BSE Sensex Gainers Today
- BSE Small Cap Gainers Today
- BSE 500 Gainers Today
- BSE A Group Losers Today
- Most Active Stocks Rs 1 to 2
- NSE Above Rs 20 Losers Today
- ANALYSE:
- TCS
- HDFC BANK
- ITC LIMITED
- ONGC
- HINDUSTAN UNILEVER
- SBI
Today's Market
Volatile Day for Indian Indices: Sensex Ends 131 Points Lower Post Rebound; Telecom and Auto Stocks Bleed(Closing)
It was a volatile day for India share markets today. The benchmark indices opened higher but turned volatile.
Related Views On News
INDOCO REMEDIES Announces Quarterly Results (3QFY20); Net Profit Up 74.9% (Quarterly Result Update)
Jan 27, 2020 | Updated on Jan 27, 2020For the quarter ended December 2019, INDOCO REMEDIES has posted a net profit of Rs 93 m (up 74.9% YoY). Sales on the other hand came in at Rs 3 bn (up 10.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.
INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)
Nov 5, 2019 | Updated on Nov 5, 2019For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.
INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)
Mar 28, 2019 | Updated on Mar 28, 2019Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.
More Views on NewsMost Popular
This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus (Profit Hunter)
Mar 17, 2020If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.
If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It. (Profit Hunter)
Mar 19, 2020Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.
Why India Will Be the Biggest Winner in a Post-Coronavirus World (The 5 Minute Wrapup)
Mar 19, 2020The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...
A Big Trading Opportunity is Coming Your Way Soon (Fast Profits Daily)
Mar 25, 2020I see a big opportunity to make fast profits on the horizon.
The Real Long-Term Impact of the Coronavirus on India (The 5 Minute Wrapup)
Mar 18, 2020My view on the impact of the Coronavirus on the Indian economy.
MoreOUR TOP 5 IDEAS
- How to Trade the Coronavirus Crash - Download this FREE Report Now
- How to Profit Even During These Times of Crisis: Vijay Bhambwani Reveals his Strategy...
- The Best Stocks For 2020 - How to Spot Multibagger Ideas. FREE Sign up!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- Find Out Our Top 7 Bluechips for 2020 Virtually FREE. Click Here Now!
TRACK INDOCO REMEDIES
- Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON INDOCO REMEDIES
INDOCO REMEDIES - INGERSOLL RAND COMPARISON
COMPARE INDOCO REMEDIES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.